Lachesis has developed a novel Rivastigmine Nasal Spray for the treatment of dementia associated with Alzheimer's and Parkinson's disease. This pharmaceutical product will allow a greater proportion of dementia patients to reach optimal and higher doses that can slow or stabilise their disease and improve their memory and activities of daily life.
Funding Source | Australian Government:$438,000.00
